HOME >> MEDICINE >> NEWS
Long-term outcomes for prostate cancer show IMRT Curative: 89 percent disease-free 8 years later

NEW YORK, September 27, 2006 -- Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate cancer patients treated with IMRT at Memorial Sloan-Kettering Cancer Center were classified into prognostic risk groups. After an average of eight years, 89 percent of the men in the favorable risk group were disease-free and none of the men in any group developed secondary cancers as a result of the radiation therapy. This report, published in the October 2006 issue of The Journal of Urology, is the first description of long-term outcomes for prostate cancer patients using IMRT.

"Our results suggest that IMRT should be the treatment of choice for delivering high-dose, external beam radiotherapy for patients with localized prostate cancer," said Dr. Michael J. Zelefsky, Chief of the Brachytherapy Service at Memorial Sloan-Kettering. "We were able to show long-term safety and long-term efficacy in a very diverse group of prostate cancer patients that we followed many for as long as ten years. Despite the fact that some patients had an aggressive form of their disease with high Gleason scores and PSA (prostate specific antigen) levels, the overwhelming majority of patients had good tumor control with neither recurrence of their original cancer nor development of second cancers, which one might have expected from the high doses of radiation," he added. Pre-treatment diagnostic evaluations were performed for all of the patients to better define their clinically localized prostate cancer. They were classified into prognostic risk groups as defined by the National Comprehensive Cancer Network guidelines (www.nccn.org). These are based on clinical characteristics including age, T stage, Gleason score, PSA level, and pre-treatm
'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3137
Memorial Sloan-Kettering Cancer Center
27-Sep-2006


Page: 1 2

Related medicine news :

1. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
2. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
3. Long-term aspirin use associated with reduced risk of dying in women
4. Long-term data on safety and effectiveness of antiobesity drugs needed
5. Long-term financial costs associated with prostate cancer treatment
6. Long-term effects of non-alcoholic fatty liver disease
7. Long-term abstinence may resolve many of the neurocognitive deficits associated with alcoholism
8. Long-term safety results released for breast cancer drugs
9. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
10. Media availability: Long-term survival of heart attack patients with shock
11. Long-term estrogen therapy linked to breast cancer risk

Post Your Comments:
(Date:6/18/2013)... St. Petersburg, FL (PRWEB) June 19, 2013 ... only 5 minutes a day could boost your health ... says Kathy Heshelow, founder of Sublime Beauty®. "It is ... been practiced for centuries but became a lost art. ... and celebrities know about Skin Brushing, and so do ...
(Date:6/18/2013)... PA, June 19, 2013 Recent studies linking ... of bullying-related suicide among young people, led the ... assemble an expert panel to focus on these ... the complex relationship between youth involvement in bullying ... among youth is a significant public health problem, ...
(Date:6/18/2013)... York (PRWEB) June 19, 2013 Parker ... the rights of victims injured by dangerous drugs and ... an Arizona woman who alleges that she was ... filed on May 30th in the U.S. District Court ... No. 2:13-cv-12677) in the multidistrict litigation entitled In Re: ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Bullying and suicide among youth is a public health problem 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
(Date:6/18/2013)... , June 19, 2013 ... Parkinson,s disease (PD) patients as add-on to levodopa ... improvement in motor symptoms in fluctuating PD patients ... Newron Pharmaceuticals S.p.A. ("Newron"), a research and ... therapies, and its partner Zambon S.p.A., a pharmaceutical ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: